Simona Tomassetti

Rimini, IT 
Rimini, IT 

Overview

Simona Tomassetti practices practicing medicine in Rimini, Italy.

Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Rimini, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

10 Total Publications

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).
Journal: Hematological oncology
Published: November 13, 2025

Frequently Asked Questions about Simona Tomassetti

Is Simona Tomassetti a top-rated expert for Myeloproliferative Neoplasms (MPN)?

MediFind is an objective health platform that identifies experts based on real-world data. Simona Tomassetti is classified as an Experienced expert for Myeloproliferative Neoplasms (MPN), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Simona Tomassetti participate in research or clinical trials?

Yes. Simona Tomassetti has published 10 articles and abstracts on conditions like Myeloproliferative Neoplasms (MPN). You can view a list of Simona Tomassetti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tomassetti's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile